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ABSTRACT
Objectives To see if a group course delivered by 
rheumatology teams using cognitive-behavioural 
approaches, plus usual care, reduced RA fatigue impact 
more than usual care alone.
Methods Multicentre, 2-year randomised controlled 
trial in RA adults (fatigue severity>6/10, no recent major 
medication changes). RAFT (Reducing Arthritis Fatigue: 
clinical Teams using CB approaches) comprises seven 
sessions, codelivered by pairs of trained rheumatology 
occupational therapists/nurses. Usual care was Arthritis 
Research UK fatigue booklet. Primary 26-week outcome 
fatigue impact (Bristol RA Fatigue Effect Numerical 
Rating Scale, BRAF-NRS 0–10). Intention-to-treat 
regression analysis adjusted for baseline scores and 
centre.
Results 308/333 randomised patients completed 
26 week data (156/175 RAFT, 152/158 Control). Mean 
baseline variables were similar. At 26 weeks, the adjusted 
difference between arms for fatigue impact change 
favoured RAFT (BRAF-NRS Effect −0.59, 95% CI –1.11 
to -0.06), BRAF Multidimensional Questionnaire (MDQ) 
Total −3.42 (95% CI –6.44 to -0.39), Living with Fatigue 
−1.19 (95% CI –2.17 to -0.21), Emotional Fatigue 
−0.91 (95% CI –1.58 to -0.23); RA Self-Efficacy (RASE, 
+3.05, 95% CI 0.43 to 5.66) (14 secondary outcomes 
unchanged). Effects persisted at 2 years: BRAF-NRS Effect 
−0.49 (95% CI −0.83 to -0.14), BRAF MDQ Total −2.98 
(95% CI −5.39 to -0.57), Living with Fatigue −0.93 
(95% CI −1.75 to -0.10), Emotional Fatigue −0.90 (95% 
CI −1.44, to -0.37); BRAF-NRS Coping +0.42 (95% CI 
0.08 to 0.77) (relevance of fatigue impact improvement 
uncertain). RAFT satisfaction: 89% scored > 8/10 vs 
54% controls rating usual care booklet (p<0.0001).
Conclusion Multiple RA fatigue impacts can be 
improved for 2 years by rheumatology teams delivering 
a group programme using cognitive behavioural 
approaches.
Trial registration number ISRCTN:52709998.
BACKGROUND
Fatigue is a significant problem for people with 
rheumatoid arthritis,1 incorporating physical 
exhaustion and cognitive impairment, with impacts 
on lifestyle, roles, relationships and emotions.2 3 
RA fatigue is persistent,4 patients feel unsupported 
by rheumatology teams and rheumatology nurses 
want help regarding fatigue management.2 5 The 
RA fatigue causal pathway remains unclear.6 
Multiple factors may form different combinations 
and weightings for each patient at each episode. A 
conceptual framework proposes three main compo-
nents: inflammation (directly or through pain, sleep 
disruption, disability), personal factors (eg, work, 
comorbidities) and cognitive behavioural elements 
(under/over activity, driven by thoughts/feelings).7 
Meta-analysis of randomised controlled trials 
(RCTs) reporting RA fatigue shows small-moderate 
effects from biological disease modifying anti-rheu-
matic drugs and physical exercise, although fatigue 
was rarely the primary outcome.8 9
Meta-analysis of psycho-educational interven-
tions reporting RA fatigue also shows small-mod-
erate benefit.10 However, only two specifically 
addressed RA fatigue.10 11 One intervention targeted 
distress, comprising 1–1 cognitive behavioural 
therapy (CBT), with an optional fatigue module.10 
The second intervention aimed to reduced fatigue 
impact, using group CBT.11 Both improved fatigue/
fatigue impact but were delivered by clinical 
psychologists, meaning they are hard to implement 
in the current NHS as few rheumatology teams 
include clinical psychologists.12 The aim of this trial 
Key messages
What is already known about this subject?
 ► Fatigue in rheumatoid arthritis is common and 
cognitive behavioural therapy can help, but few 
rheumatology units have clinical psychologists 
to deliver it.
What does this study add?
 ► This study demonstrates that rheumatology 
nurses and occupational therapists using 
cognitive behavioural approaches can reduce 
fatigue impact with both short-term and long-
term effects.
How might this impact on clinical practice or 
future developments?
 ► All seven clinical teams were able to deliver 
this intervention, suggesting future clinical 
implementation is feasible.
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was to see if usual care plus a group course delivered by rheu-
matology teams using cognitive-behavioural approaches (CBA) 
reduced RA fatigue impact more than usual care alone.
METHODS
The detailed methods have been published13 and a summary is 
provided here.
Trial design
UK, 7-centre randomised controlled trial of group CBA for 
fatigue self-management plus usual care (1–1 fatigue informa-
tion) versus usual care alone.
Participants
Eligible patients were aged >18 years with confirmed RA14 and 
fatigue severity >6/10 on a Numerical Rating Scale (NRS),15 
which they considered recurrent or persistent. Exclusion criteria 
were recent changes to glucocorticoids (6 weeks) or major RA 
medication (16 weeks) or insufficient English to participate 
in group discussions. Patients were approached in clinic or 
by mailshots to departmental databases. Ethics approval was 
obtained (East of England Norfolk 13/EE/0310), the trial regis-
tered (ISRCTN 52709998) and patients gave written informed 
consent.
Interventions
RAFT is the group course for RA fatigue using CBT approaches 
previously facilitated by a clinical psychologist.11 RAFT 
comprises seven sessions (weeks 1–6 for 2 hours, consolida-
tion week 14 for 1 hour), addressing behaviours likely to be 
related to fatigue and their underpinning thoughts and feel-
ings (see online supplementary data), as previously published.13 
Tutors use exploratory questioning, goal-setting and peer-sup-
port to enhance self-efficacy (belief that you can succeed with 
an activity), prompting changes in self-management.16 17 RAFT 
was manualised for codelivery by pairs of rheumatology nurses/
occupational therapists, who trained together over 4 days and 
delivered an observed course locally before the RCT.13
Usual care was the Arthritis Research UK fatigue self-man-
agement booklet, based on the original RAFT intervention,18 
provided to and discussed with each patient for approxi-
mately 5 min by the research nurse at the baseline visit (ie, 
pre-randomisation).
Outcomes
The primary outcome was fatigue impact at 26 weeks, collected 
by the central trial team by telephone using the Bristol RA 
Fatigue Numerical Rating Scale (BRAF-NRS Effect).15 Other 
fatigue elements were severity, coping (BRAF-NRSs) and overall 
impact (BRAF Multidimensional Questionnaire, BRAF-MDQ).15 
Clinical status comprised pain (NRS), disability (Modified 
Health Assessment Questionnaire, MHAQ),19 sleep (item from 
Pittsburgh Sleep Quality Index),20 disease activity (DAS2821 at 
weeks 0 and 26, replaced at other time-points by self-report 
(sPDAS2),22 23 mood (Hospital Anxiety and Depression scale, 
HADS),24 quality of life (global question, Arthritis Impact 
Measurement Scale, AIMS)25 and leisure activities (discretionary 
activity subscale, Valued Life Activities, VLA).26 Self-efficacy and 
helplessness underpinning processes were assessed (RA Self-Ef-
ficacy scale (RASE), Arthritis Helplessness Index (AHI)).27 28 
Outcomes were measured at weeks 0, 6, 26, 52, 78 and 104. At 
weeks 10 and 18, fatigue was measured for exploratory analysis 
of the week 14 consolidation session. Satisfaction with RAFT/
booklet (26 weeks) and social contact (weeks 52, 104) comprised 
unvalidated questions. Economic and qualitative evaluations will 
be reported elsewhere.
Sample size
With 90% power and a two-sided significance of 0.05, 73 
patients/arm would detect 1.46 units difference in fatigue impact 
(effect size 0.54), equal to 75% of the 1.95 units difference 
achieved by a CBT therapist (SD 2.7, effect size 0.77).11 Poten-
tial for clustering effects from groups/tutors increased this to 75/
arm and allowing for 2 year attrition (50%) we aimed to recruit 
150/arm.29
Randomisation
Seven centres each recruited four trial cohorts over 2 years. Once 
a centre recruited 10–16 participants (cohort), informed consent 
and baseline assessments were conducted. Computer-generated 
randomisation for that cohort was performed by the Bristol 
Randomised Trials Collaboration; thus, randomisation was strat-
ified by centre, and within centres by cohort (1-4). Allocation 
was 1:1 with the RAFT arm receiving the additional patient if 
numbers were uneven. Patients randomised to RAFT but unable 
to attend their course were offered subsequent courses. All 
patients eligible at screening were accepted, even if they had 
become ineligible by baseline (medication/fatigue changes) while 
awaiting full cohort recruitment, mirroring the pragmatic nature 
of chronic illness interventions.
Blinding
RAFT group courses meant blinding of patients and clinicians 
was impossible, but data were analysed blind to arm allocation.
Statistical methods
Analysis followed a predefined plan, used STATA V.14.1.1, 
reported using CONSORT guidelines.30 Analyses were 
conducted on an intention-to-treat (ITT) basis without impu-
tation of missing data, adjusting for baseline value and centre. 
Primary effectiveness analysis used linear regression to estimate 
an adjusted mean difference comparing fatigue impact at 26 
weeks (primary outcome) between groups as randomised. Anal-
ysis was repeated including 20 sets of imputed missing primary 
outcome data. The multiple imputation model included all vari-
ables that were part of the ITT primary analysis, variables poten-
tially related to fatigue impact (fatigue severity, pain, self-rated 
and nurse-rated disease activity) and baseline variables that were 
associated with missingness of the primary outcome. Secondary 
analysis compared groups across 26, 52, 78 and 104 weeks using 
a mixed effects model (treatment arm baseline measure of the 
outcome, centre and timepoint as fixed effects and participant 
as a random effect to account for the repeated measures nature 
of the data). Further secondary analyses of the primary outcome 
included: restricting the analysis to baseline-eligible participants 
(ie, fatigue severity >6/10); a Complier Average Causal Effect 
(CACE) analysis to investigate the efficacy of the intervention 
(based on treatment compliance status) for comparison with the 
ITT estimate of the offer of the intervention31 and investigation 
of potential clustering by centre and group. Secondary outcomes 
at 26 weeks were examined using linear regression for continuous 
outcomes and logistic regression for binary outcomes (adjusted 
for baseline measure of the outcome and centre) and over 26, 
52, 78 and 104 weeks using the mixed effects models above. 
Potential predictors of fatigue impact change were modelled 
using stepwise deletion. Exploratory analyses assessed the effects 
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Figure 1 Participant flowchart. CBT, cognitive behavioural therapy.
of a potential tutor learning curve, the week 14 consolidation 
session and individual self-efficacy (RASE) questions at 26 weeks 
(t-test).
Patient involvement
Patient partners (Rooke, Robinson) brought experiential knowl-
edge of RA fatigue and received the original CBT intervention.11 
They advised on outcomes, questionnaires, handouts, recruit-
ment and supported tutor training; Rooke provided advice on 
the tutor manual, attended project meetings and interpreted 
results.
RESULTS
Four consecutive cohorts of 9–16 patients were randomised in 
each of 7 centres over 2 years (n=333) (figure 1), with similar 
numbers across centres (see online supplementary data). Six 
of 158 patients randomised to usual care alone withdrew 
before week 26. While 6 of 175 patients randomised to RAFT 
attended a later course than planned (with fresh baseline data), 
14 patients could not meet any local course dates and did 
not receive RAFT. Of the 161 patients who received RAFT, 
4 withdrew for personal/health reasons (having attended 1–3 
of the 7 sessions) and 1 before week 10. Therefore 156/175 
RAFT patients (89.9%) and 152/158 control patients (96.0%) 
provided primary week 26 outcome data; 153/175 RAFT and 
147/158 control patients provided week 104 data (87.4%, 
93.0%).
RAFT delivery
All 7 rheumatology centres provided at least two clinicians 
and of 15 trained, 14 went on to deliver RAFT: 4 nurse/occu-
pational therapist pairs, 1 occupational therapist pair and 2 
nurse pairs. Tutors had been qualified for a mean 18 years 
(6–30), with 5.3 years rheumatology experience (0–17); 10 
had experience of group work, of whom 4 reported knowl-
edge of goal-setting or CBT. All hospitals delivered four 
RAFT courses. Tutor pairs remained unchanged, apart from 
one centre where tutor absence was covered by the remaining 
tutor codelivering one course with a trainer and one with a 
colleague who had previously observed. Seven of the 196 
RAFT sessions (28 courses of 7 sessions) were delivered by a 
single tutor due to absence (3.6%). Independent monitoring of 
two sessions of every course confirmed tutor fidelity to RAFT 
content, delivery and CB principles.
RAFT attendance
At randomisation, RAFT groups averaged six patients (5-8). 
Patients attended a mean 5.85 of their 7 RAFT sessions (SD 
1.63), with 136 (87.2%) attending 5–7. All 156 RAFT patients 
attended their Session 1 (definition of having received RAFT), 
and each of the individual Sessions 2–7 was attended by >75% 
randomised patients. No related adverse events reported.
Baseline data
Total 308/333 randomised patients completed primary 26 
week outcome data. Baseline characteristics were similar 
between arms, being primarily female (RAFT 125/156, 80.1%, 
control 121/152, 79.6%), >60 years old (RAFT median 63.7, 
IQR 54.2, 69.9; control 61.8, IQR 54.4, 69.6) and a median 
10 year disease duration (RAFT IQR 5, 19; control 3, 20). 
Baseline clinical data were similar between arms (table 1) with 
high fatigue impact (mean BRAF-NRS Effect >7/10) that was 
slightly higher than fatigue severity, low perceived ability to 
cope with fatigue, relatively high baseline disease activity 
(mean DAS28>4.2), moderate pain, low disability, moderate 
self-efficacy and helplessness. The 25 patients who withdrew 
had similar characteristics (see online supplementary data). 
During the trial, normal clinical management meant patients 
had changes to major RA medications but this was not different 
between arms (see online supplementary data).
Primary outcome
At week 26, mean BRAF-NRS impact was reduced by 1.36 
units (p<0.001) in RAFT compared with 0.88 in controls 
(p<0.004).32 33 Regression analysis showed a difference 
between changes in fatigue impact NRS of −0.59 in favour 
of RAFT (p=0.03, table 2), giving a standardised effect size of 
0.36 (adjusted difference in mean/pooled baseline SD).
The primary analysis was repeated excluding patients who 
had fallen below the BRAF-NRS Severity>6/10 eligibility 
criterion between screening and baseline (23/156 RAFT, 
23/152 control). For baseline-eligible patients, a larger effect 
was seen in favour of RAFT, with an adjusted mean difference 
between arms for fatigue impact of −0.82 (95% CI −1.40 to 
-0.24, p=0.01).
Analysis on 20 sets of imputed data gave almost identical 
results (adjusted mean difference between arms for fatigue 
impact −0.58), therefore no further imputation was used. 
CACE analysis supported the finding of a larger effect from 
RAFT in those who ‘complied’ with the intervention compared 
with the ITT estimate of the ‘offer’ of the intervention (CACE 
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Table 1 Baseline clinical data
Control (n=158) RAFT (n=175)
n (%)* Mean (SD) n (%)* Mean (SD)
Fatigue
  BRAF-NRS Effect (0–10) 152 (96.2) 7.23 (1.6) 156 (89.1) 7.10 (1.7)
  BRAF-NRS Severity (0–10) 142 (89.9) 6.85 (1.57) 152 (86.9) 6.89 (1.57)
  BRAF-NRS Coping (0–10)† 142 (89.9) 4.84 (2.09) 152 (86.9) 5.16 (2.08)
  BRAF-MDQ impact overall (0–70) 142 (89.9) 40.39 (12.99) 152 (86.9) 40.42 (12.70)
  BRAF-MDQ Physical (0–22) 142 (89.9) 16.19 (3.21) 152 (86.9) 16.12 (3.39)
  BRAF-MDQ Emotional (0–12) 142 (89.9) 6.71 (3.31) 152 (86.9) 6.55 (3.18)
  BRAF-MDQ Cognitive (0–15) 142 (89.9) 7.58 (4.04) 152 (86.9) 7.54 (4.00)
  BRAF-MDQ Living with (0–21) 142 (89.9) 9.90 (5.18) 152 (86.9) 10.21 (5.05)
Pain NRS (0–10) 142 (89.9) 5.57 (2.10) 152 (86.9) 5.70 (2.12)
Disability MHAQ (0–3) 142 (89.9) 0.76 (0.51) 151 (86.3) 0.75 (0.53)
Quality of life AIMS VAS (0–100) 141 (89.2) 49.89 (20.44) 152 (86.9) 49.16 (22.27)
Disease activity
  Assessed—DAS28 (0.96+) 145 (91.8) 4.23 (1.11) 147 (84.0) 4.22 (1.30)
  Self-report—sPDAS2 (2.4–7.9) 142 (89.9) 4.36 (0.99) 151 (86.3) 4.44 (1.06)
Anxiety HADS (0–21) 142 (89.9) 8.01 (4.45) 151 (86.3) 7.29 (4.08)
Depression HADS (0–21) 142 (89.9) 6.79 (3.94) 151 (86.3) 7.18 (3.59)
Valued life activities (0–3) 142 (89.9) 1.08 (0.60) 151 (86.3) 1.16 (0.61)
Helplessness AHI (5-30) 142 (89.9) 18.98 (4.74) 152 (86.9) 19.03 (4.67)
Self-efficacy RASE (28-140)†† 142 (89.9) 104.38 (11.34) 151 (86.3) 102.49 (11.51)
Sleep quality 142 (89.9) 149 (85.1)
  Very good‡ 5 (3.5%) 9 (6.0%)
  Fairly good‡ 58 (40.9%) 48 (32.2%)
  Fairly bad‡ 51 (35.9%) 56 (37.6%)
  Very bad‡ 28 (19.7%) 36 (24.2%)
*Percentage of total randomised (Control 158, RAFT 175).
†Higher score=better outcome.
‡Percentage of questionnaires returned.
AHI, Arthritis Helplessness Index; AIMS, Arthritis Impact Measurement Scale; BRAF-MDQ, Bristol RA Fatigue Multidimensional Questionnaire; BRAF-NRS, Bristol RA Fatigue 
Numerical Rating Scale; HADS, Hospital Anxiety and Depression Scale; MHAQ, Modified Health Assessment Questionnaire; RASE, RA Self-Efficacy.
Table 2 Primary outcome of fatigue impact at 26 weeks
Control RAFT Adjusted* mean 
difference
(95% CI) P valuen (%)†
Week 0
Mean (SD)
Week 26
Mean (SD) n (%)†
Week 0
Mean (SD)
Week 26
Mean (SD)
BRAF-NRS effect 152 (96.2) 7.23 (1.6) 6.36 (2.42) 156 (89.1) 7.10 (1.7) 5.74 (2.41) −0.59 (−1.11 to -0.06) 0.03
*Linear regression adjusted for baseline BRAF-NRS impact and centre.
†Percentage of total randomised (Control 158, RAFT 175).
BRAF-NRS, Bristol RA Fatigue Numerical Rating Scale.
treatment effect estimate −0.69). However, CACE methods 
could be deemed inappropriate as 14 patients randomised to 
but not attending RAFT had no follow-up data (see online 
supplementary data). No evidence of clustering was demon-
strated: log-likelihood of linear mixed model −696.44 vs 
log-likelihood of model not adjusting for clustering −696.48 
(p=0.96).
Primary outcome over two years
Difference between the arms for fatigue impact was main-
tained over 2 years (figure 2). RAFT patients had a BRAF-NRS 
Impact score that was on average better than controls over 
2 years with an adjusted mean difference of −0.49 (95% CI 
−0.83 to -0.14, p=0.01) (see online supplementary data). The 
mixed effects model conducted on baseline-eligible patients 
again showed a slightly larger treatment effect with an average 
adjusted mean difference over 2 years of −0.58 (95% CI 
−0.95 to -0.22, p=0.002).
Secondary outcomes
There was a difference between arms at 26 weeks in favour of 
RAFT for overall fatigue impact, emotional fatigue, living with 
fatigue (BRAF-MDQ Overall and subscales) and self-efficacy 
(RASE) (table 3). Findings were similar over 2 years, when better 
outcomes for fatigue coping (BRAF-NRS Coping) also emerged 
for RAFT whereas self-efficacy was no longer significant 
(table 4). There was no difference between arms for the other 13 
secondary outcomes, including fatigue severity (tables 3 and 4).
Patient satisfaction
At 26 weeks, 89% of RAFT patients (133/150) rated course 
satisfaction >8/10 compared with 54% (75/139) controls 
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Figure 2 BRAF-NRS Impact scores (0–10) over weeks 0–104 by trial 
arm. BRAF-NRS, Bristol RA Fatigue Numerical Rating Scale.
Table 3 Adjusted mean difference between arms in secondary outcomes at 26 weeks
Control RAFT Adjusted mean 
difference*
(95% CI) P value Effect sizen (%)† Mean (SD) n (%)† Mean (SD)
Fatigue
  BRAF-NRS Severity (0–10) 142 (89.9) 6.13 (2.30) 152 (86.9) 5.91 (2.22) −0.24 (−0.75 to 0.27) 0.35
  BRAF-NRS Coping (0-10)‡ 142 (89.9) 5.32 (2.42) 152 (86.9) 5.25 (2.33) −0.15 (−0.69 to 0.39) 0.58
  BRAF-MDQ Impact Overall (0–70) 142 (89.9) 34.74 (16.41) 152 (86.9) 31.51 (16.02) −3.42 (−6.44 to -0.39) 0.03 0.27
  BRAF-MDQ Physical (0–22) 142 (89.9) 14.40 (5.23) 152 (86.9) 13.72 (4.91) −0.68 (−1.78 to 0.42) 0.23
  BRAF-MDQ Emotional (0–12) 142 (89.9) 5.36 (3.79) 152 (86.9) 4.37 (3.51) −0.91 (−1.58 to -0.23) 0.01 0.28
  BRAF-MDQ Cognitive (0–15) 142 (89.9) 6.55 (4.16) 152 (86.9) 5.89 (4.35) −0.66 (−1.45 to 0.13) 0.10
  BRAF-MDQ Living with (0–21) 142 (89.9) 8.43 (5.68) 152 (86.9) 7.53 (5.43) −1.19 (−2.17 to -0.21) 0.02 0.23
Pain NRS (0–10) 142 (89.9) 5.24 (2.41) 152 (86.9) 5.47 (2.32) 0.16 (−0.33 to 0.65) 0.51
Disability MHAQ (0–3) 142 (89.9) 0.70 (0.51) 151 (86.3) 0.71 (0.54) 0.02 (−0.06 to 0.10) 0.67
Quality of Life AIMS VAS (0–100) 141 (89.2) 47.70 (23.04) 152 (86.9) 47.22 (23.46) −0.33 (−5.13 to 4.65) 0.90
Disease Activity:
  Assessed—DAS28 (0.96+) 145 (91.8) 4.10 (1.31) 147 (84.0) 4.13 (1.38) 0.02 (−0.21 to 0.24) 0.88
  Self-report—sPDAS2 (2.4–7.9) 142 (89.9) 4.33 (1.04) 151 (86.3) 4.44 (1.13) 0.05 (−0.16 to 0.26) 0.63
Anxiety HADS (0–21) 142 (89.9) 7.56 (4.48) 151 (86.3) 6.65 (4.36) −0.33 (−0.95 to 0.29) 0.30
Depression HADS (0–21) 142 (89.9) 6.42 (4.06) 151 (86.3) 6.22 (3.76) −0.50 (−1.14 to 0.14) 0.13
Valued Life Activities (0–3) 142 (89.9) 1.07 (0.62) 151 (86.3) 1.09 (0.67) −0.05 (−0.15 to 0.05) 0.34
Helplessness AHI (5-30) 142 (89.9) 17.47 (5.46) 152 (86.9) 16.92 (5.06) −0.61 (−1.65 to 0.43) 0.25
Self-efficacy RASE (28-140)‡ 142 (89.9) 104.67 (13.31) 151 (86.3) 106.26 (14.78) 3.05 (0.43 to 5.66) 0.02 0.27
Sleep quality:
  Very good§ 9 (6.3%) 17 (11.4%) 0.75 (0.47 to 1.17)¶ 0.21
  Fairly good§ 65 (45.8%) 64 (43.0%)
  Fairly bad§ 51 (35.9%) 51 (34.2%)
  Very bad§ 17 (12.0%) 17 (11.4%)
*Linear regression adjusted for baseline measure of outcome and centre.
†Percentage of total randomised (Control 158, RAFT 175).
‡Higher score=better outcome.
§Number of patients (% questionnaires returned).
¶OR from ordinal logistic regression.
AHI, Arthritis Helplessness Index; AIMS, Arthritis Impact Measurement Scale; BRAF-MDQ, Bristol RA Fatigue Multidimensional Questionnaire; BRAF-NRS, Bristol RA Fatigue 
Numerical Rating Scale; HADS, Hospital Anxiety and Depression Scale; MHAQ, Modified Health Assessment Questionnaire; RASE, RA Self-Efficacy.
rating booklet satisfaction (p<0.0001). Additionally, 96% of 
RAFT patients (144/150) were very likely to recommend it to 
others (scoring >8/10) compared with 68% (95/139) controls 
recommending the booklet (p<0.001). At 52 weeks, 20% of 
RAFT patients (n=35) had made further contact with their 
RAFT group, and 9% (16) at 104 weeks.
Potential predictors of fatigue impact change
The final linear regression model suggested worse outcome at 
26 weeks was predicted by being female (0.75 unit increase in 
BRAF-NRS Effect, 95% CI 0.08 to 1.41, p=0.03) and higher 
baseline disease activity (1 unit increase in baseline DAS28 asso-
ciated with 0.25 unit increase in BRAF-NRS Effect, 95% CI 0.02 
to 0.49, p=0.04).
Exploratory analyses (see online supplementary data): The 
difference between arms in mean fatigue impact change was 
smallest in cohort 1 (−0.37 BRAF-NRS Effect) and greatest in 
cohort 4 (−0.82), suggesting possible tutor learning over time 
(the study was not powered to test this). The adjusted mean 
differences between arms for fatigue impact, coping with fatigue 
and emotional fatigue were greater at week 18 than week 10, 
suggesting benefit from the week 14 consolidation session, but 
could reflect random variation over time. RASE addresses self-ef-
ficacy for RA self-management, and six RASE items demonstrated 
a difference between arms for change in favour of RAFT at week 
26: relaxation, pacing, accepting fatigue, asking for help, using 
relaxation tapes and avoiding things that cause pain.
DISCUSSION
RAFT, a seven-session group CBA course for RA fatigue 
self-management delivered by rheumatology nurses and occu-
pational therapists, reduced fatigue impact beyond usual 
care both at 6 months and 2 years. RAFT had high patient 
attendance and satisfaction. Improvements were also seen in 
emotional fatigue, living with fatigue, coping with fatigue and 
self-efficacy.
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Table 4 Mixed effects models examining effect of raft on secondary 
outcomes over 2 years
Adjusted 
mean 
difference* 95% CI P value
Fatigue
  BRAF-NRS Severity (0–10) −0.17 −0.54 to 0.20 0.38
  BRAF-NRS Coping (0–10)† 0.42 0.08 to 0.77 0.02
  BRAF-MDQ Impact Overall (0–70) −2.98 −5.39 to -0.57 0.02
  BRAF-MDQ Physical (0–22) −0.64 −1.45 to 0.17 0.12
  BRAF-MDQ Emotional (0–12) −0.90 −1.44 to -0.37 0.001
  BRAF-MDQ Cognitive (0–15) −0.53 −1.14 to 0.08 0.09
  BRAF-MDQ Living with (0–21) −0.93 -1.75 to -0.10 0.03
Pain NRS (0–10) 0.01 −0.38 to 0.40 0.94
Disability MHAQ (0–3) 0.01 −0.07 to 0.08 0.86
Quality of Life AIMS VAS (0–100) −0.02 −3.91 to 3.86 0.99
Disease activity sPDAS2 (2.4–7.9) 0.03 −0.15 to 0.20 0.77
Anxiety HADS (0–21) −0.40 −0.96 to 0.15 0.16
Depression HADS (0–21) −0.49 −1.06 to 0.08 0.09
Valued Life Activities (0–3) −0.06 −0.14 to 0.03 0.22
Helplessness AHI (5-30) −0.27 −1.12 to 0.58 0.54
Self-efficacy RASE (28-140)† 1.31 −0.80 to 3.42 0.23
Sleep Quality 0.74‡ 0.44 to 1.27 0.28
*Adjusted for baseline measure of outcome and centre.
†Higher score=better outcome (for all other scales lower score=better outcome).
‡OR from ordinal logistic regression.
AHI, Arthritis Helplessness Index; AIMS, Arthritis Impact Measurement Scale; BRAF-
MDQ, Bristol RA Fatigue Multidimensional Questionnaire; BRAF-NRS, Bristol RA 
Fatigue Numerical Rating Scale; HADS, Hospital Anxiety and Depression Scale; 
MHAQ, Modified Health Assessment Questionnaire; RASE, RA Self-Efficacy.
Improvements in fatigue impact demonstrated in usual care 
alone were not seen in the previous RCT, where the control 
was one general self-management group session of didactic 
information.11 The usual care fatigue booklet18 in this RCT 
was written by the team following the original RCT.12 A qual-
itative study suggested that patients felt the booklet made 
them feel more responsible for taking actions to manage their 
fatigue.34 The brief booklet discussion with the nurse in this 
RCT may have had a greater effect than a patient picking up 
a booklet in clinic.
The amount of fatigue impact change that might be clini-
cally important for people with RA is unknown. The minimal 
clinically important difference (MCID) for RA fatigue severity 
scales averages 10%,35–37 while multiple sclerosis fatigue 
impact MCID is 15%.38 39 RAFTs demonstrated 19% change 
in fatigue impact and usual care 12% (–1.36, –0.88 units) are 
thus probably clinically meaningful.
There was no treatment difference between arms for fatigue 
severity. Longitudinal studies demonstrate RA fatigue severity 
is largely stable with most having a persistent moderately high/
high trajectory.5 40 Symptom severity differs from impact: 
patients can report low impact from severe symptoms and 
vice versa.41 42 Impact may be the product of interactions 
between symptom severity, personal importance and perceived 
coping.43 The 2 year treatment difference in favour of RAFT 
for coping with fatigue might reflect reduced personal impor-
tance of fatigue, thus improving fatigue impact even with 
persistent fatigue severity. RAFT participants may have made 
a shift in how they view and manage fatigue, finding ways to 
reduce its impact.44
The 2-year effects of RAFT on fatigue coping suggest 
that patients’ newly acquired fatigue self-management skills 
became embedded. Core self-management skills taught in 
CB approaches may have translated into improved coping. 
Overall self-efficacy favoured RAFT at 26 weeks with changes 
in 6/28 RASE items of key fatigue self-management issues 
addressed in RAFT. Self-efficacy was no longer significant at 
2 years, possibly reflecting the dominance of the 22 general 
RA self-management items in the RASE score over time since 
RAFT, compared with the focused fatigue coping NRS (ie, a 
measurement issue).
Strengths and limitations
The study’s external validity was strengthened by involving 
7 hospitals, 14 tutors, broad entry criteria and strong patient 
and public involvement. The pragmatic trial design accommo-
dated features of real clinical practice: natural variations in 
medication, fatigue, group size, session attendance and tutor 
availability. Collection of the primary outcome by telephone 
gave high return rates.
There was no control for social effects of RAFT groups: seven 
sessions of didactic information would not reflect usual care 
and likely incur high attrition. In the original RCT, patients 
reported benefit from interactions with other patients, but 
considered tutors more important, otherwise patients would 
have ‘pulled one another down’.44 Delay between screening 
and baseline assessment was inevitable while building cohorts 
for randomisation, and some patients no longer had eligible 
fatigue severity scores at baseline. However, RAFT still had an 
overall treatment effect, with a greater effect in baseline-eli-
gible participants. Delays would be shorter in clinical practice 
as only sufficient patients for a RAFT group need be recruited. 
Six RAFT patients requested a later course and had a fresh 
baseline assessment, collected after randomisation. Major 
medication changes might influence fatigue but changes were 
not different between arms and remission through optimal 
medication does not resolve problematic fatigue.45 We did 
not collect follow-up data on 25 patients who withdrew, but 
imputing missing data did not change the primary outcome 
analysis. RAFT patients were not asked to rate the usual care 
booklet.
Implications for research
Codelivery by a rheumatology professional and a patient 
(bringing experiential knowledge of RA fatigue) could be eval-
uated,46 as could delivery in physical long-term conditions 
with fatigue (multiple sclerosis, Parkinson’s disease) and the 
MCID for the BRAF-NRS Effect established.
Implications for healthcare
The CBA intervention was delivered by clinical rheuma-
tology nurses and occupational therapists, addressing the lack 
of rheumatology psychologists.12 Similar success has been 
demonstrated in multiple sclerosis fatigue.47 RAFT delivery 
by clinical teams was feasible: all planned RAFT courses were 
delivered, tutor absence was managed and patient atten-
dance high. Increasing group size to 8–10 patients would be 
feasible, as would including patients with other inflammatory 
rheumatic diseases and fatigue.48 49 Several RCT centres now 
deliver RAFT clinically.
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